论文部分内容阅读
目的观察莫沙比利对老年2型糖尿病胃轻瘫的临床疗效。方法采用随机单盲对照试验。将80例老年糖尿病胃轻瘫患者随机分成2组,莫沙比利组40例,予莫沙比利5 mg,tid,餐前服用;对照组40例,予安慰剂餐前服用。疗程为12个月。2组患者在入选时及治疗期间每3个月测定空腹血糖(FBG)和餐后2 h血糖(PBG),在入选时和疗程结束时行胃排空试验。结果 2组患者经治疗后FBG均比治疗前有所下降,且随着治疗时间的延长,FBG值越低;PBG也均比治疗前有所下降,但差异无统计学意义(P>0.05)。莫沙比利组治疗后胃半排空时间较治疗前明显降低[(82.35±12.64)minvs(103.80±22.24)min,P<0.05];而对照组治疗前后差异未见有统计学意义(P>0.05)。结论莫沙比利能改善部分老年糖尿病胃轻瘫患者胃排空功能,有利于控制血糖。
Objective To observe the clinical efficacy of mosapride on type 2 diabetic gastroparesis in the elderly. Methods Randomized single-blind control trial. Eighty elderly patients with diabetic gastroparesis were randomly divided into two groups, 40 patients in the mosapride group, to mosapride 5 mg, tid, taken before meals; the control group, 40 patients were given placebo before meals. Treatment for 12 months. Fasting blood glucose (FBG) and 2-hour postprandial blood glucose (PBG) were measured in both groups at the time of enrollment and every 3 months of treatment, and gastric emptying was performed at enrollment and at the end of the course of treatment. Results The FBG in both groups decreased after treatment, and the FBG value decreased with the extension of treatment time. PBG also decreased compared with that before treatment, but the difference was not statistically significant (P> 0.05) . The half-time of gastric emptying in the mosapride group was significantly lower than that before treatment [(82.35 ± 12.64) min vs (103.80 ± 22.24) min, P <0.05], while there was no significant difference in the control group before and after treatment > 0.05). Conclusion Mosapride can improve gastric emptying in some elderly patients with gastroparesis and is good for controlling blood sugar.